Is Mersana Therapeutics Inc (MRSN) overvalued? · rev $40.5M
Mersana Therapeutics Inc (MRSN) is a biotechnology company listed on NASDAQ.
This page asks whether Mersana Therapeutics Inc (MRSN) looks expensive on cached numbers — not a short thesis.
Latest reported MRSN revenue for 2024-12-31 was $40.5M. Net income was -$69.2M. Revenue was up 9.9% from 2023-12-31 to 2024-12-31. MRSN currently screens at market cap $145.4M.
MRSN currently screens at market cap $145.4M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next MRSN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the MRSN stock page for the full model, not this heading.
Not investment advice.